SCHEMBL6419265

SCHEMBL6419265

FC(F)(F)c1cc(C(F)(F)F)cc(C(P)(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ccc3ccccc3c2-c2c(C(P)(c3cc(C(F)(F)F)cc(C(F)(F)F)c3)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)ccc3ccccc23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 1/20 0.41
P2RX3 P56373 1/20 0.41
P2RX4 Q99571 1/20 0.41
P2RX7 Q99572 1/20 0.41
KCNJ11 Q14654 2/20 0.37
MAPT P10636 5/20 0.37
KDM4E B2RXH2 4/20 0.37
HSD17B10 Q99714 4/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GLA P06280 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5509954 0.89 KCNJ11 (0.44) KCNJ11MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL6418428 0.84 HPRT1 (0.40) KCNJ11MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL6420827 0.84 CYP1A2 (0.37) KCNJ11MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL3955070 0.81 HSD17B10 (0.47) MAPTKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL6419124 0.81 CYP1A2 (0.38) KCNJ11MAPTHSD17B10ALDH1A1HPGD
SCHEMBL8011621 0.80 HSD11B1 (0.42) KCNJ11MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL8022205 0.79 KCNJ11 (0.41) KCNJ11MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL8010776 0.78 KCNJ11 (0.39) KCNJ11MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL8023616 0.75 KCNJ11 (0.40) KCNJ11MAPTHSD17B10ALDH1A1HPGD
SCHEMBL6423409 0.74 HPRT1 (0.40) KCNJ11MAPTKDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956133-B2 Process for hydroformylating an olefin OXENO OLEFINCHEMIE GMBH (DE) 2005-10-18 US disclosed
US-6924389-B2 Method for producing diphosphines and the use thereof OXENO OLEFINCHEMIE GMBH (DE) 2005-08-02 US disclosed
US-20050038272-A1 Process for preparing diphosphines OXENO OLEFINCHEMIE GMBH (DE) 2005-02-17 US disclosed
US-20040110979-A1 Process for preparing diphosphines EVONIK DEGUSSA GMBH (DE) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110979-A1 Process for preparing diphosphines CYTH2, DOHH, HRH2 P2RX1 1508/4885P2RX3 1721/4885P2RX4 1566/4885
US-20050038272-A1 Process for preparing diphosphines HRH2, HRH3, HRH4 P2RX1 549/4885P2RX3 646/4885P2RX4 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.